New Edition of China’s National Essential Drugs List Released:
Types of Insulin and Oral Hypoglycemic Drug Increased by 150%, with Varieties being Newer and More Complete!

National Essential Drugs List
--2018 Edition--
|
Type |
2012 edition |
2018 edition |
|||
|
Variety name |
Dosage form, specification |
Variety name |
Dosage form, specification |
||
|
Insulin |
Insulin |
Animal-sourced insulin injection (short-acting, intermediate-acting, long-acting, and premixed): 400 units Recombinant human insulin injection (short-acting, intermediate-acting, and premixed 30R): 300 units, 400 units |
Insulin |
Animal-sourced insulin injection (short-acting, intermediate-acting, long-acting, and premixed): 300 units, 400 units Recombinant human insulin injection (short-acting, intermediate-acting, and premixed 30R): 300 units, 400 units |
|
|
|
|
Insulin Glargine |
Injection: 3ml:300 units (prefilled), 3ml:300 units (refill) |
||
|
Non-insulin secretagogue |
Thiazolidinedione (glitazone) |
|
|
Pioglitazone |
Tablet: 15mg, 30mg Capsule: 15mg, 30mg |
|
Biguanide |
Metformin |
Tablet, enteric-coated (tablet, capsule), sustained-release tablet: 0.25g, 0.5g Capsule: 0.25g |
Metformin |
Tablet, enteric-coated (tablet, capsule), sustained-release tablet: 0.25g, 0.5g Capsule: 0.25g Sustained-release capsule: 0.25g |
|
|
SGLT-2 inhibitor |
|
|
Dapagliflozin |
Tablet: 5mg, 10mg |
|
Read More
Related News
Made-in-China New Drugs: The Game and Breakthrough in the Over - 4 - Billion Market
Lezhi September 5, 2025
US appeals court allows Sanofi, Regeneron to continue selling PCSK9 inhibitor Praluent
firstwordpharma February 10, 2017
Acorda's experimental Parkinson's disease drug CVT-301 hits main goal of late-stage trial
firstwordpharma February 10, 2017 You may like
Factory Supply 99% Purity Recombinant Protein IGF-1 LR3 Insulin-like Growth Factor-I
Insulin Degludec/Insulin Detemir
Factory Supply 99% Human Long Arg 3 Insulin-like Growth Factor-I (Recombinant Protein) IGF-1 LR3 CAS
Insulin pen needle
Refillable Insulin Pen, Insulin Injection Devices For Diabetes patients self-administration
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation! Subscribe
Note: You can unsubscribe from the alerts at any time. Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation! Subscribe
Note: You can unsubscribe from the alerts at any time. Most popular
The Rise of Biosimilars: Regulatory Pathways and Market Outlook
Nurah Ekhlaque
Sep 19, 2025
Digitalization in Procurement: From AI Forecasting to Blockchain Traceability
Saher Haider
Sep 19, 2025
Methodology Validation in Chinese Pharmacopoeia 2025: How to Report Accuracy and Precision
Xing Xing
Sep 12, 2025
| |||||










(All Rights Reserved)